The has announced grants totaling $8.7 million as part of a new initiative to investigate the early stages of and identify ways to prevent type 1 diabetes (T1D).
The five grant recipients will observe hundreds of thousands of newborns and children across the United States, Europe, and Australia; design a plan to analyze the massive quantity of data charting the history and progression of T1D; and develop an infrastructure to perform intervention clinical trials, with a primary focus on delaying or stopping the development of the disease. The grantees include (German Research Center for Environmental Health) and the , which were awarded $762,113 and $885,765, respectively, over two years to design the infrastructure required for global population-based prevention clinical trials.
In addition, the was awarded $2.4 million over two years in support of its Environmental Determinants of Diabetes in the Young (TEDDY) campaign, which has enrolled more than eight thousand eligible newborns in a long-term observational study; will receive $4.5 million over three years in support of its Environmental Determinants of Islet Autoimmunity (ENDIA) study, which will investigate candidate environmental exposures and gene-environment interactions that could contribute to the development of islet autoimmunity and T1D in early life; and , which was awarded $169,806 over six months to review existing data from completed prevention clinical trials of T1D and other autoimmune diseases to determine whether they can inform the longer-term goal of designing a prevention intervention trial.
"While curing T1D has been a research focus for many decades, that goal is still a long way off, unfortunately. The launch of this initiative represents the first steps in a long-term effort to prevent this chronic disease," said David Panzirer, a trustee of the Helmsley Charitable Trust. "We are delighted to support ambitious observational studies like TEDDY and ENDIA, and through new European partnerships we are eager to develop an infrastructure to perform intervention clinical trials, which is one of the main goals of the T1D Prevention Initiative."